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Abstract
Background: The UK incidence of pancreatic ductal adenocarcinoma (PDAC) is approximately 9/100,000 population
compared with 1–2/100,000 for biliary tract cancer (BTC). This study explores the incidence of these cancers over time and
the influence of socio-demographic and geographic factors in a UK primary care cohort.
Methods: This study uses data from a large UK primary care database, The Health Improvement Network (THIN). All adult
patients contributing data to THIN between January 2000 and December 2010 were included. Annual incidence rates were
calculated, adjusted for age, gender, time period, deprivation score (Townsend quintile) and strategic health authority.
Results: From 2000–2010, the annual incidence of PDAC increased by an average of 3% per year (95% CI 1.00–4.00%) and
BTC by 4% (95% CI 2.00–6.00%). Incidence of both cancers increased steeply with age and was higher in men. BTC was
associated with increasing deprivation (most deprived versus least deprived quintile (OR: 1.45 [95% CI: 1.17, 1.79.]).
Conclusions: The overall incidence of both cancers is low but increasing. Variations in incidence may reflect changes in
coding practice or increased exposure to associated risk factors.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the tenth com-
monest cancer in the UK with an incidence of approximately 9 per
100,000 population, compared with 1–2 cases per 100,000
population for Biliary Tract Cancer (BTC) [1]. Long-term survival
is poor; 5-year survival is less than 4% for both tumours [1,2].
Typically these cancers are diagnosed late when patients have
advanced disease and curative surgical resection is not possible.
Survival rates improve dramatically if diagnosed early [3].
Rates of both PDAC and BTC vary significantly worldwide.
The highest incidence of PDAC is seen in Northern Europe and
North America [4] and is 3–4 times higher than rates seen in
tropical countries [5]. Global variations in BTC incidence are
even more marked; the highest incidence reported is from north
eastern Thailand (96 per 100,000 men) [6], and is attributed to
endemic levels of liver fluke infestation (Clonorchis sinensis and
Opisthorchis viverinni) and chronic typhoid carriage [6].
Variation in incidence of PDAC and BTC has also been
reported over time. In the UK, data from the Office for National
Statistics (ONS) showed that the incidence of PDAC and BTC
between 1998 and 2007 was stable [2]. However in the United
States, over the last decade, rates of PDAC have increased by
1.2% per year [4].
Most PDAC and BTC tumours occur sporadically and
therefore variation in incidence over time and between popula-
tions is largely thought to be the result of differences in life styles
and exposure to environmental risk factors [7]. The most
consistent and strongly associated risk factor associated with
PDAC is cigarette smoking [8–15]. A recent meta-analysis of 82
studies found the overall risk of PDAC for current smokers was
1.74 (95% CI 1.61–1.87). After smoking cessation the frequency of
PDAC gradually diminishes, but does not return to baseline for ten
years [16]. Chronic medical conditions such as diabetes mellitus,
chronic pancreatitis [15,17] and obesity [18], have also been
associated with PDAC. BTC also occurs more frequently with
increasing age [6], and has been associated with several risk factors
including primary sclerosing cholangitis [19], intraductal stones
and rare congenital cystic diseases such as Caroli’s disease [20].
Other less established but potential risk factors for BTC include
inflammatory bowel disease, chronic viral hepatitis, cirrhosis,
smoking, diabetes, obesity and excess alcohol consumption [20–
22].
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Regardless of incidence, overall mortality of these two tumours
is predicted to increase in the US and Europe over the next
decade, unless there are substantial improvements in screening for
these tumours to effect earlier diagnosis [23,24]. Identifying
epidemiological factors that could potentially be used to define
high-risk groups, which would be suitable for targeted screening or
surveillance, is increasingly being seen as a important way to
improve survival in PDAC and BTC [8,25]. This study therefore
explores time trends and the influence of sociodemographic and
geographic factors on the incidence of PDAC and BTC by
examining a large UK primary care database.
Methods
Setting
We used data from 562 UK general practices that provided
data to The Health Improvement Network (THIN) from 1st
January 2000 to 31st December 2010. We only used practices
meeting standards for acceptable levels of data recording, which
was defined as achieving both acceptable mortality recording
(AMR) [26] and acceptable computer usage (ACU), which is
recognised as recording an average of two prescriptions or medical
records per patient per year [27]. The total registered patient
population during this time period was more than ten million,
comprising a follow up of more than 75 million patient years.
Data source
The THIN database contains primary care records from
approximately 6% of the UK population (http://csdmruk.
cegedim.com/). The database is collated from electronic case
notes, which have been submitted by a subset of General
Practitioners (GP) who have opted to provide anonymous data
for research. During a consultation, information on presenting
symptoms, diagnoses (including cancer diagnoses) and referrals to
secondary care are recorded within the electronic records as Read
codes, which is a hierarchical coding system used in UK primary
care [28]. The database links data to the UK Strategic Health
Authority (SHA) based on a patient’s postal code. Deprivation was
examined using quintiles of Townsend score from ‘one’ (least
deprived) to ‘five’ (most deprived). The Townsend score is a
combined measure of owner-occupation, car ownership, over-
crowding and unemployment based on a patient’s postcode and
linkage to population census data for 2001 for approximately 150
households in that postal area.
Study population
All patients over the age of 18 with a Read code diagnosis for
PDAC or BTC during the study period were included in the study.
Read code lists of diagnostic terms for PDAC and BTC were
developed using previously described methodology [29]. Data
from the first 6 months of registration were excluded to prevent
the accidental inclusion of retrospective incident cases of PDAC or
BTC. Data from practices not achieving an appropriate AMR or
ACU level were also excluded. Date for entry into the study cohort
was determined by compliance with all of these parameters.
Cohort exit was defined as the earliest date of the following:
diagnosis with PDAC or BTC, left the GP practice, died, last data
collection by THIN or end of study period (December 31st 2010).
The total number of patient years between cohort entry and exit
defined the denominator for the incidence calculations.
Statistical analyses
Crude incidence rates were calculated by dividing the number
of cases by the Person years at risk (PYAR). Confidence intervals
(95% CI) were calculated assuming a Poisson distribution, as the
event of interest was rare. Stratified incidence rates were
calculated across gender, 10-year age-band, time period, social
deprivation and strategic health authority. Poisson regression was
used to calculate adjusted incidence rate ratios (IRRs). Patients
with missing data on the Townsend score were grouped together
and included in the regression analysis. The statistical analysis
undertaken did compare time period as categorical vs. continuous
but found no evidence that the former was a better fit and that this
should be incorporated into the subsequent analysis. Wald tests
were used to identify significant associations with the categorical
variables and any significant interactions. The GP practice was
included as a random effect to account for any data clustering. All
p-values were two-tailed and a value of less than 5% (#0.05) was
considered statistically significant. All analyses were done using
Stata version 11.2. The THIN Scheme was approved by the
National Health Service South-East Multi-centre Research Ethics
Committee in 2002 and the present study was approved by the
Scientific Review Committee at University College London.
Results
3284 patients with PDAC and 1007 patients with BTC were
included in this study. The crude incidence of PDAC was 14.5 per
100,000 person-years. In women the incidence was 15% (95%CI;
9 to 21%) lower than in men after accounting for age and time
period. From 2000 to 2010, the incidence of PDAC in this cohort
increased by an average of 3% each year (95%CI; 1 to 4%)
(Table 1 and Figure 1).
The incidence of PDAC increased sharply with age and was 4.3
(95%CI; 3.84 to 4.81) times more common in those aged 70–79
and 5.88 (95%CI; 5.24 to 6.61) times more common those aged
80–89, compared to those aged 50–59, after accounting for gender
and time period (Table 2). In PDAC there was no association
between incidence and social deprivation.
The crude incidence of BTC was 4.4 per 100,000 person-years.
The incidence was 5% (95%CI; 8 to16%) lower in women after
accounting for age and time period. Since 2000, the incidence of
BTC in this cohort, has increased by an average of 4% each year
(95% CI; 2 to 6%) (Table 1 and Figure 1).
The incidence of BTC, like PDAC, increased sharply with age.
BTC was most common in those over 60 and incidence peaked in
those over 80. BTC was 6.37 (95%CI; 5.14 to 7.91, P,0.001)
times more common in those aged 80–89 compared with those
aged 50–59, after accounting for gender and time period. The
incidence of BTC also differed in accordance with social
deprivation. Significantly higher rates of BTC were seen in the
most socially deprived group (1.45; 95%CI: 1.17 to 1.79)
compared to the most affluent (Table 2). There were also regional
differences in BTC, for example the North East of England (1.65,
95% CI: 1.18 to 2.32.) had a significantly higher incidence of BTC
compared to London (Table 3).
Discussion
This study explored incidence trends in PDAC and BTC
between 2000 and 2010 in a large UK primary care cohort.
PDAC was three times more common than BTC. The overall
incidence of these cancers was low but increased during the study
period. Both tumours were more common in men and incidence
rose sharply with increasing age, which is similar to trends
reported previously [2,6,30–32]. The incidence of BTC also varied
according to area and sociodemographic status, being more
common in the North East of the UK and in the least affluent
social groups.
Incidence Trends in Pancreatic and Biliary Tract Cancer
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Figure 1. Time trends in PDAC and BTC from 2000–2010 - annual incidence with 95% confidence intervals.
doi:10.1371/journal.pone.0108498.g001
Table 1. Incidence rates of PDAC and BTC per 100,000 population, between 2000 and 2010 in primary care across a range of
sociodemographic variables.
PDAC BTC
Cases Person years (105) Incidence rate (95% CI) Cases Person years (105) Incidence rate (95% CI)
Overall 3284 2300 14.50 (14.00–15.00) 1007 2300 4.40 (4.20–4.70)
Male 1591 1100 14.40 (13.70–15.10) 457 1100 4.10 (3.80–4.50)
Female 1693 1200 14.60 (13.90–15.30) 550 1200 4.70 (4.30–5.10)
Ageband
30 17 520 0.30 (0.20–0.50) 16 520 0.30 (0.20–0.50)
40 105 520 2.00 (1.60–2.40) 33 520 0.60 (0.40–0.90)
50 431 450 9.50 (8.60–10.40) 121 450 2.70 (2.20–3.20)
60 829 360 23.20 (21.60–24.80) 246 360 6.90 (6.00–7.80)
70 1034 250 40.60 (38.10–43.10) 323 250 12.70 (11.30–14.10)
80 868 160 54.80 (51.20–58.60) 268 160 16.90 (14.90–19.10)
Townsend score
No Townsend score available 73 75 9.70 (7.60–2.30) 23 75 3.10 (1.90–4.60)
1 (Most affluent) 870 610 14.20 (13.30–15.20) 240 610 3.90 (3.40–4.40)
2 788 510 15.40 (14.40–16.60) 230 510 4.50 (3.90–5.10)
3 645 450 14.30 (13.20–15.40) 192 450 4.30 (3.70–4.90)
4 546 370 14.60 (13.40–15.90) 171 370 4.60 (3.90–5.30)
5 (Most deprived) 362 240 14.90 (13.40–16.60) 151 240 6.20 (5.30–7.30)
Year of Diagnosis
2000 154 130 11.80 (10.00–13.80) 42 130 3.20 (2.30–4.30)
2001 207 150 13.40 (11.60–15.40) 73 150 4.70 (3.70–5.90)
2002 225 180 12.70 (11.10–14.40) 62 180 3.50 (2.70–4.50)
2003 237 200 12.00 (10.50–13.60) 67 200 3.40 (2.60–4.30)
2004 307 210 14.50 (12.90–16.20) 100 210 4.70 (3.80–5.70)
2005 353 220 15.80 (14.20–17.60) 83 220 3.70 (3.00–4.60)
2006 334 230 14.60 (13.10–16.20) 92 230 4.00 (3.20–4.90)
2007 344 230 14.80 (13.20–16.40) 131 230 5.60 (4.70–6.70)
2008 381 240 16.10 (14.50–17.80) 116 240 4.90 (4.00–5.90)
2009 389 240 16.50 (14.90–18.20) 127 240 5.40 (4.50–6.40)
2010 353 230 15.10 (13.60–16.80) 114 230 4.90 (4.00–5.90)
doi:10.1371/journal.pone.0108498.t001
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The changes in incidence of these tumours over time, was in
contrast to recent data from the Office for National Statistics,
which found that between 1998 and 2007 the overall incidence of
these tumours was relatively stable in the UK [2] although a rising
incidence has been reported in some parts of Europe [33,34] and
the United States [4]. Reasons for this potential rise in incidence
are unclear, but may reflect an aging population [35], and
associated risk factors becoming increasingly common in these
populations. Several risk factors have been associated with PDAC,
including cigarette smoking [8–15], diabetes, chronic pancreatitis
[15,17] and obesity [18]. Prevalence of obesity and diabetes has
increased steadily in the UK during the study period and
continues to increase annually [36,37]. By the end of the study
period in 2010, 26.1% of UK adults were reported to be obese
[36,37], one of the highest rates in Europe [37]. Between 1996 and
2005 the prevalence of type II diabetes in the UK increased from
2.8% to 4.3% [38].
Alternatively the changes in incidence seen in this database may
reflect improved coding practice during the study period. Other
studies have demonstrated that the accuracy of solid organ tumour
diagnosis recording within the THIN database, has improved over
time [39]. In addition, the recording of smoking status within
THIN has also improved during the study period and by the end
of 2008, was similar to national data from the Good Housekeeping
survey [40].
An association between social deprivation in this study was only
demonstrated between BTC and lower socioeconomic status.
Given that PDAC is believed to be strongly associated with a
number of risk factors such as smoking, diabetes and obesity,
which are more prevalent in lower socioeconomic groups, this
trend was somewhat unexpected. However other groups have also
not consistently found there to be an association between PDAC
and social deprivation [30,31,41–46]. Indeed a recent detailed
examination of trends in death rates in PDAC from 1970 to 2009
concluded that the patterns seen could not be explained by
associated risk factors alone [47].
In BTC, other studies have also found an increased prevalence
in the most deprived sociodemographic groups [48]. The
incidence of BTC was also found to be higher in the North East
of England, which may reflect higher rates of social deprivation in
this area. Rates of smoking and smoking-related diseases such as
chronic obstructive airways disease [49] and lung cancer [50] are
also higher in the North East. However smoking has not
consistently been identified as a risk factor for BTC and further
studies will be required to fully explain this trend.
Strengths and limitations of the study
A significant strength of this study is that it includes a large
cohort of primary care patients, 3284 with PDAC and 1007
patients with BTC. Primary care datasets have some specific
advantages over ONS data in research terms as they are linked to
more clinical information such as risk factors, prescribed
medications and presenting symptoms. Although an association
with these factors was outside the scope of this particular study, it
would be a subject for future work.
Data within the THIN database is not yet linked to histological
data from secondary care or death certification data and recording
is dependent on correct coding by GP. All General Practices
submitting data to THIN received formal training in recording
data for epidemiological research after 2003, prior to that data was
recorded based on clinical need and individual clinician practice.
A previous study found that during the early 2000 s solid organ
tumours including PDAC were under-recorded within the THIN
database compared to ONS data [39]. However, the recording
Table 2. Results of multivariable Poisson regression to identify socio-demographic variables in PDAC and BTC in the primary care
setting.
PDAC BTC
IRR 95% CI Overall p- IRR 95% CI Overall
value p-value
(Wald test) (Wald test)
Gender (Male reference) 0.85 0.79,0.91 0.95 0.84,1.08
Ageband
30 0.03 0.02,0.06 0.12 0.07,0.19
40 0.21 0.17,0.26 0.24 0.16,0.35
50 (reference) 1.00 Reference 1.00 Reference
60 2.43 2.16,2.73 2.57 2.06,3.19
70 4.30 3.84,4.81 4.76 3.86,5.86
80 5.88 5.24,6.61 ,0.001 6.37 5.14,7.91
Increase per calendar year (2000–2010) 1.03 1.01,1.04 1.04 1.02,1.06
Townsend score
No Townsend score available 0.90 0.70, 1.15 0.89 0.58, 1.38
1 (Most affluent) 1.00 Reference 1.00 Reference
2 1.04 0.94,1.15 1.07 0.89,1.28
3 1.00 0.90,1.11 1.03 0.85,1.25
4 1.04 0.93,1.16 1.10 0.90,1.34
5 (Most deprived) 1.09 0.96,1.24 0.5784 1.45 1.17,1.79 0.0104
IRR: adjusted incidence rate ratios.
doi:10.1371/journal.pone.0108498.t002
Incidence Trends in Pancreatic and Biliary Tract Cancer
PLOS ONE | www.plosone.org 4 September 2014 | Volume 9 | Issue 9 | e108498
T
a
b
le
3
.
R
e
su
lt
s
o
f
a
m
u
lt
iv
ar
ia
b
le
P
o
is
so
n
re
g
re
ss
io
n
to
id
e
n
ti
fy
d
if
fe
re
n
ce
in
in
ci
d
e
n
ce
o
f
P
D
A
C
an
d
B
T
C
p
e
r
1
0
0
0
0
p
o
p
u
la
ti
o
n
ac
ro
ss
p
ri
m
ar
y
ca
re
p
ra
ct
ic
e
s
w
it
h
in
st
ra
te
g
ic
h
e
al
th
au
th
o
ri
ti
e
s
in
th
e
U
K
.
P
D
A
C
B
T
C
C
a
se
s
P
e
rs
o
n
y
e
a
rs
(1
0
5
)
In
ci
d
e
n
ce
ra
te
(9
5
%
C
I)
IR
R
(9
5
%
C
I)
O
v
e
ra
ll
p
-
v
a
lu
e
(W
a
ld
te
st
)
C
a
se
s
P
e
rs
o
n
y
e
a
rs
(1
0
5
)
In
ci
d
e
n
ce
ra
te
(9
5
%
C
I)
IR
R
(9
5
%
C
I)
O
v
e
ra
ll
p
-
v
a
lu
e
(W
a
ld
te
st
)
Ea
st
M
id
la
n
d
s
1
4
6
9
8
1
.5
0
(1
.2
6
–
1
.7
6
)
1
.1
3
(0
.8
9
–
1
.4
3
)
4
7
9
8
0
.4
8
(0
.3
5
–
0
.6
4
)
1
.0
6
(0
.7
4
–
1
.5
3
)
Ea
st
o
f
En
g
la
n
d
2
5
2
1
7
0
1
.4
7
(1
.3
0
–
1
.6
6
)
1
.0
9
(0
.8
9
–
1
.3
4
)
6
5
1
7
0
0
.3
8
(0
.2
9
–
0
.4
8
)
0
.8
2
(0
.5
9
–
1
.1
4
)
Lo
n
d
o
n
2
2
6
2
0
0
1
.1
2
(0
.9
8
–
1
.2
8
)
1
.0
0
(R
e
fe
re
n
ce
)
8
1
2
0
0
0
.4
0
(0
.3
2
–
0
.5
0
)
1
.0
0
(R
e
fe
re
n
ce
)
N
o
rt
h
Ea
st
1
0
5
6
8
1
.5
4
(1
.2
6
–
1
.8
7
)
1
.0
8
(0
.8
3
–
1
.4
0
)
5
7
6
8
0
.8
4
(0
.6
4
–
1
.0
9
)
1
.6
5
(1
.1
8
–
2
.3
2
)
N
o
rt
h
W
e
st
3
6
7
2
4
0
1
.5
1
(1
.3
6
–
1
.6
7
)
1
.1
4
(0
.9
4
–
1
.3
7
)
1
2
5
2
4
0
0
.5
1
(0
.4
3
–
0
.6
1
)
1
.1
0
(0
.8
3
–
1
.4
7
)
N
o
rt
h
e
rn
Ir
e
la
n
d
9
4
6
1
1
.5
5
(1
.2
5
–
1
.9
0
)
1
.2
0
(0
.9
2
–
1
.5
6
)
3
6
6
1
0
.5
9
(0
.4
2
–
0
.8
2
)
1
.3
1
(0
.8
8
–
1
.9
4
)
Sc
o
tl
an
d
2
9
7
2
3
0
1
.2
8
(1
.1
4
–
1
.4
3
)
0
.9
6
(0
.7
9
–
1
.1
6
)
1
0
9
2
3
0
0
.4
7
(0
.3
8
–
0
.5
7
)
0
.9
9
(0
.7
4
–
1
.3
2
)
So
u
th
C
e
n
tr
al
4
3
4
3
0
0
1
.4
6
(1
.3
2
–
1
.6
0
)
1
.0
5
(0
.8
7
–
1
.2
6
)
9
9
3
0
0
0
.3
3
(0
.2
7
–
0
.4
0
)
0
.7
1
(0
.5
3
–
0
.9
6
)
So
u
th
Ea
st
C
o
as
t
3
0
4
2
2
0
1
.4
1
(1
.2
5
–
1
.5
7
)
1
.0
1
(0
.8
3
–
1
.2
3
)
8
5
2
2
0
0
.3
9
(0
.3
1
–
0
.4
9
)
0
.8
2
(0
.6
0
–
1
.1
2
)
So
u
th
W
e
st
4
5
6
2
5
0
1
.8
0
(1
.6
4
–
1
.9
7
)
1
.2
2
(1
.0
1
–
1
.4
6
)
1
1
4
2
5
0
0
.4
5
(0
.3
7
–
0
.5
4
)
0
.9
0
(0
.6
7
–
1
.2
0
)
W
al
e
s
1
8
3
1
2
0
1
.5
0
(1
.2
9
–
1
.7
4
)
1
.0
9
(0
.8
7
–
1
.3
5
)
5
4
1
2
0
0
.4
4
(0
.3
3
–
0
.5
8
)
0
.9
0
(0
.6
4
–
1
.2
8
)
W
e
st
M
id
la
n
d
s
2
9
9
2
1
0
1
.4
1
(1
.2
6
–
1
.5
8
)
1
.0
3
(0
.8
5
–
1
.2
6
)
9
0
2
1
0
0
.4
2
(0
.3
4
–
0
.5
2
)
0
.9
0
(0
.6
6
–
1
.2
2
)
Y
o
rk
sh
ir
e
&
H
u
m
b
e
r
1
2
1
8
9
1
.3
6
(1
.1
2
–
1
.6
2
)
1
.0
0
(0
.7
7
–
1
.2
8
)
0
.3
5
8
4
5
8
9
0
.5
0
(0
.3
7
–
0
.6
7
)
1
.0
7
(0
.7
4
–
1
.5
4
)
0
.0
0
0
3
IR
R
:
ad
ju
st
e
d
in
ci
d
e
n
ce
ra
te
ra
ti
o
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
8
4
9
8
.t
0
0
3
Incidence Trends in Pancreatic and Biliary Tract Cancer
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e108498
accuracy of PDAC did improve consistently over the following
years and by 2007 was similar to ONS data (standardised
incidence ratio .0.8) [39].
A potential limitation of this study is that incidence trends for
BTCs were considered as a whole without consideration of tumour
subtypes e.g. intrahepatic or extrahepatic cholangiocarcinoma or
gallbladder cancer. In recent years although overall rates of BTC
have been reported to be stable, steep rises in incidence have been
seen in intrahepatic cholangiocarcinomas [51,52]. Reasons for this
trend are debated and may reflect changes in environmental risk
factors or changes to the way perihilar tumours are classified [53].
The accuracy of recording of BTC subtypes has not been validated
within this database so all BTC cases in this cohort were
considered as a whole.
Conclusions
The overall incidence of PDAC and BTC is low but rising in
this UK primary care cohort and is likely to reflect improved
coding practice within primary care during the study period. In
BTC a higher incidence was seen in the North East of the UK and
in the most socially deprived groups, which may reflect variations
in local and environmental risk factors.
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